The PCAC advisory committee: what it is and why it matters

The short version: PCAC is a small FDA advisory committee whose recommendations decide which compounds 503A pharmacies are allowed to make.

TL;DR

• PCAC stands for Pharmacy Compounding Advisory Committee.
• It reviews bulk drug substances and recommends whether they should be on the FDA's allowed list for 503A compounding.
• Its votes are advisory. The FDA makes the final decision through Federal Register notice.

What it is

The PCAC (in plain English: the advisory committee inside the FDA that reviews compounds and recommends whether 503A pharmacies should be allowed to make them) is a small group of pharmacists, physicians, and consumer representatives. It exists under the Federal Food, Drug, and Cosmetic Act, specifically Section 503A, which sets the rules for compounding pharmacies that prepare medications for individual patients.

How it works

Think of the PCAC like a vetting committee at the door of a kitchen. The kitchen is the 503A compounding pharmacy. The vetting committee reads the science on each ingredient — published studies, safety data, whether the compound is already an FDA-approved drug, whether there is unmet medical need — and recommends "yes, this can be used" or "no, this should be removed." The kitchen does not get to make the call alone, and the committee does not get to make it alone either. The FDA listens to the committee, then publishes its decision.

Who asks about it

People come to this topic when a peptide they are reading about gets reclassified, when a physician mentions Category 2 status, or when news headlines reference a "PCAC vote." The committee's work is technical, but the consequences are practical — they shape which compounds can legally be prepared by 503A pharmacies for patients.

What the research says

The FDA publishes the PCAC charter, meeting agendas, transcripts, and voting records on its public website (FDA — Pharmacy Compounding Advisory Committee). Each formal action — adding or removing a compound from the bulk substances list — is announced through the Federal Register (Federal Register — Food and Drug Administration agency page). Several peptides were placed in Category 2 by the FDA in 2023 following PCAC review. FDA removed most of them from Category 2 in September 2024 and April 2026, after their nominations were withdrawn. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list.

What to know before considering it

PCAC meetings are public and have an open comment period. Committee recommendations are not the final word — the FDA can accept, modify, or set aside a vote. Patients who want access to a specific peptide can submit public comments, but the formal change happens through Federal Register notice.

The Halftime POV

The PCAC is one of the lesser-known but most consequential committees for the peptide field. Its meetings shape which compounds 503A pharmacies can prepare, which then shapes who can access what under prescription. Watching the agenda is part of doing this work seriously.

Related reading:

• Category 1 vs Category 2 peptides: the access framework
• What the July 2026 PCAC meeting could change
• 503A vs 503B compounding pharmacies explained

---

FAQ

Q: What is the PCAC? A: The PCAC, or Pharmacy Compounding Advisory Committee, is the FDA advisory committee that reviews and recommends which bulk drug substances should be added to or removed from the list compounders are allowed to use under Section 503A of the Food, Drug, and Cosmetic Act.

Q: Does the PCAC make final decisions? A: No. The PCAC is advisory. Its votes inform the FDA's decisions, which are then formalized through Federal Register notice. The committee can recommend a compound be added or removed, but the final action belongs with the agency.

Q: What happened at the July 2026 PCAC meeting? A: FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026. It reviewed seven peptides for the Section 503A bulk drug substances list: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. Several of them were previously in Category 2. The committee voted to recommend adding six of them. It voted against recommending emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision.

---

Disclaimer

Several peptides discussed in this article — including KPV and others — were previously in FDA's Category 2. FDA removed them from Category 2 (September 2024 or April 2026, depending on the peptide). As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. In February 2026, HHS Secretary Robert F. Kennedy Jr. said in a podcast interview that FDA would soon make more peptides accessible. That was not a formal proposal; the formal step was FDA's April 2026 change to its category list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA — Pharmacy Compounding Advisory Committee
• Federal Register — Food and Drug Administration agency page

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.